Researchers are exploring the development of antibodies against medically important target proteins, including those considered undruggable. A novel approach using kinetically controlled biomolecular probes and structural bioinformatics has been applied to targets such as human KRAS G13D. This method may help identify new druggable spaces and create potential therapeutic opportunities.